Dostarlimab's 2022 Trial in a Specific Form of Rectal Cancer

Facebook ↗WhatsApp ↗

First published September 30, 2022.

What the trial showed in 2022, and what followed

The initial paper reported complete clinical responses in 12 patients with mismatch-repair-deficient rectal cancer. The study was conducted in New York. That result was not proof that 18 Australian patients had been permanently cured.

Who it applies to. Only about 5% to 10% of patients with locally advanced rectal cancer have a mismatch-repair-deficient (dMMR) tumour; the result says nothing about other rectal or bowel cancers.

The 2024 update. At the 2024 ASCO meeting the same Memorial Sloan Kettering team reported that all 42 patients who had completed dostarlimab treatment had a clinical complete response, assessed by MRI, endoscopy and rectal examination; in the first 24 patients the response had lasted for a median follow-up of 26.3 months, and none of the patients had needed chemotherapy or radiation afterwards. US NCCN guidelines added PD-1 blockade as an option for dMMR rectal cancer in May 2023, but as of June 2024 dostarlimab was not approved anywhere for first-line treatment of this cancer. A clinical complete response means no detectable tumour, and follow-up is still too short to call these patients permanently cured. (Update, October 2026: the expanded Memorial Sloan Kettering study was published in the New England Journal of Medicine on 27 April 2025: all 49 patients with rectal cancer who completed treatment had a clinical complete response, and across 117 patients with several kinds of early dMMR tumours, 82% of the 103 who completed treatment had a complete response, with 92% recurrence-free survival at two years (AJMC, 27 April 2025). On 19 October 2026 the US FDA granted dostarlimab (Jemperli) accelerated approval for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer, based mainly on the AZUR-1 trial (The ASCO Post, 19 October 2026; GSK, 19 October 2026).)

Dostarlimab's 2022 Trial in a Specific Form of Rectal Cancer

Scientists and researchers are heralding a new drug as a potential breakthrough in the fight against cancer following publication of results from a trial at Memorial Sloan Kettering in New YorkOriginal source .


The drug, known as Dostarlimab, produced clinical complete responses in the first 12 patients who completed treatment for a specific mismatch-repair-deficient form of rectal cancer .


At the time the paper was written, 12 patients had completed treatment. It reads:


"A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumour on magnetic resonance imaging."


The initial report described clinical complete responses in 12 patients with at least six months of follow-up — not, as first reported here, proof that cancer had vanished in all 18 patients after two years. Even so, the result was so astonishing that Dr Luis A. Diaz Jr. of New York's Memorial Sloan Kettering Cancer Centre said that it is:


"The first time this has happened in the history of cancer."


Dr. Diaz, who ran the study published the findings in the New England Journal of Medicine.


Dostarlimab is from a new branch of drugs that involve laboratory created molecules that act as antibodies in the human body. It is a checkpoint inhibitor: rather than attacking cancer cells directly, it blocks the PD-1 “brake” on immune cells, so that the immune system can attack the tumour.


Dr Alan P. Venook, who was not involved in the project, told the New York Times that a cancer trial in which all initially reported patients had a clinical complete response was 'unheard of'.


While this was a small trial, the treatment will now likely be offered on a wider scale, meaning that firmer results can be found. The source article also said that about 100,000 Australians are diagnosed with bowel cancer every year. Official figures are much lower: Cancer Australia reports 14,904 new colorectal cancer cases in 2021 and estimates 14,784 for 2025.


Scientists also hope that this new approach to cancer, which appears to have fewer side effects than traditional chemotherapy, can be engineered to fight other types of cancers.


Recently, the first-ever human trials involving a genetically modified virus designed to fight cancer cells began, while immunotherapy approaches have also been met with great promise, indicating that we may be on our way to eventually defeating one of the world's biggest killers. (Correction: this was the first human trial of one particular virus, CF33-hNIS (Vaxinia), whose first patient was dosed in May 2022 (City of Hope and Imugene, 17 May 2022); genetically modified cancer-fighting viruses had already been tested in people, and one, Imlygic, a genetically modified herpes simplex virus, was approved by the US FDA for melanoma on 27 October 2015 (Amgen, 27 October 2015).)


[Based on reporting by: Ladbible]


Sources for the added context

COMMENTS